Pfizer (NYSE: PFE )
recently lost a battle to preserve its patent coverage on Celebrex,
but it's not all bad news for this pharmaceutical giant. The company's
Prevnar-13 pneumococcal vaccine is shaping up as a
stronger-than-expected product, with comprehensive outcomes data
potentially supporting much broader recommendations for use and a larger
addressable market. Better still, it's not just Prevnar that could
drive higher vaccine sales for Pfizer in the coming years.
Click here to continue:
Will Pfizer Inc's Vaccine Strategy Pay Off?
No comments:
Post a Comment